Our body uses oxy gen to metabolize food and to eliminate toxins and waste through oxidation. Cells undergo a variety of bio logical responses when placed in hypoxic conditions, including switch in energy metabolism from oxidative phosphorylation to glycolysis and activation of signaling pathways that regulate proliferation, angiogenesis and death. Cancer cells have adapted these pathways, allow ing tumours to survive and even grow under hypoxic conditions, and tumour hypoxia is associated with poor prognosis and resistance to therapy. In most solid tumours, the resistance to cell death is a conse quence of the suppression of apoptosis. In this context, CELLFOOD, the physiological mo dulator aimed to make available oxygen on demand with marked antioxidant effects, was inves tigated for apoptosis and cancer prevention.

selleck CF, is a nutraceutical supple ment whose constituents, including 78 trace elements and minerals, 34 enzymes, 17 amino acids, electrolytes and deuterium sulphate, are all naturally occurring sub stances which are essential to the bodys biochemical functions. We tested the activity of CF on 12 different cell lines, 2 normal and 10 cancerous. Our results showed that CF reduced cell proliferation in a dose dependent manner in all the cancer cell lines used. Mesothelioma and colon cancer were the most sensitive cell lines to the nutraceutical. Mesothelioma, which commonly originates from mesothelial cells lining the pleural cavity, is an aggressive tumour that is difficult to treat. The number of MM patients is pre dicted to increase because of the long latency of the disease and historical exposure to asbestos.

Colorectal cancer is a major cause of morbidity and mortality throughout the world. CF suppresses cell growth by apoptosis in MSTO 211 and HCT 116 cell lines. In particular, we found that CF caused an increase of sub G1 and a reduction of G1 in MSTO 211, and a cell cycle arrest in G1 in HCT116. We speculated that CF induced proliferative block was irreversible {going here| inhibitor|selleckchem|selleckchem|PF-04620110 clinical trial due to the significant increase in population with a sub G1 and G1 DNA content observed in the treated cells as compared to the untreated ones. Evidence of apoptosis in MSTO 211 and HCT 116 cells on CF treatment was observed in western blot. CF induces apoptosis by a caspase dependent pathway. Among the caspase family members, caspase 3 is known to be one of the key executioners of apoptosis because caspase 3 activation causes the cleavage or degradation of downstream important substrates, like PARP, which is the hallmark of caspase dependent apoptosis. In our ex periments, caspase 3 activation and PARP cleavage were detected in CF treated MSTO 211 and HCT 116.